Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Controversies in Bronchogenic Carcinoma Following Lung Transplantation Type of Transplant Operation and Role of Screening

Controversies in Bronchogenic Carcinoma Following Lung Transplantation Type of Transplant... EDITORIAL Controversies in Bronchogenic Carcinoma Following Lung Transplantation Type of Transplant Operation and Role of Screening Selim M. Arcasoy, MD, FACP, FCCP*† ung transplantation has become an accepted treatment modality for patients with Ladvanced lung disease. Despite two decades of experience, limited long-term survival, caused predominantly by the development of chronic allograft rejection and infection, remains the main shortcoming of lung transplantation. However, recent reports from large transplant centers and the International Heart and Lung Transplant Registry reveal improving survival in lung transplant recipients. Data also show a progressive increase in the mean age of lung transplant recipients with chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis as the two main indications of lung transplantation. All of these trends are expected to result in a higher rate of medical complications in transplant recipients, particularly the development of malignancy. Malignancy has long been observed as a complication of chronic immunosuppres- sive therapy in organ transplant recipients. Dysregulation of antitumor immune surveil- lance, pretransplant environmental exposures such as tobacco smoke and sunlight, and a variety of viral infections are the main underlying mechanisms contributing to the development of malignancy. The cumulative risk of developing one or more malignancy, excluding nonmelanoma skin http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Controversies in Bronchogenic Carcinoma Following Lung Transplantation Type of Transplant Operation and Role of Screening

Arcasoy, Selim M.
Journal of Thoracic Oncology , Volume 3 (12) – Dec 1, 2008
Download PDF
2 pages

Loading next page...
 
/lp/wolters-kluwer-health/controversies-in-bronchogenic-carcinoma-following-lung-transplantation-hnnXPsEqgI

References (7)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e318190b2c0
pmid
19057259
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Controversies in Bronchogenic Carcinoma Following Lung Transplantation Type of Transplant Operation and Role of Screening Selim M. Arcasoy, MD, FACP, FCCP*† ung transplantation has become an accepted treatment modality for patients with Ladvanced lung disease. Despite two decades of experience, limited long-term survival, caused predominantly by the development of chronic allograft rejection and infection, remains the main shortcoming of lung transplantation. However, recent reports from large transplant centers and the International Heart and Lung Transplant Registry reveal improving survival in lung transplant recipients. Data also show a progressive increase in the mean age of lung transplant recipients with chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis as the two main indications of lung transplantation. All of these trends are expected to result in a higher rate of medical complications in transplant recipients, particularly the development of malignancy. Malignancy has long been observed as a complication of chronic immunosuppres- sive therapy in organ transplant recipients. Dysregulation of antitumor immune surveil- lance, pretransplant environmental exposures such as tobacco smoke and sunlight, and a variety of viral infections are the main underlying mechanisms contributing to the development of malignancy. The cumulative risk of developing one or more malignancy, excluding nonmelanoma skin

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Dec 1, 2008

There are no references for this article.